TenQ · fact sheet · filings current to · price as of
e.l.f. Beauty (ELF)
A mixed picture - strengths and real weaknesses - 18 of 36 checks passed.
Latest close : $109.67, +2.1% on the day; -25.2% from the 52-week high. Refreshed every trading night.
Full analysis: report · all charts. Financial statements are computed from SEC EDGAR XBRL filings, current to . The share price and everything built on it (market cap, multiples, yields, the Value and Trend checks) are refreshed every trading night; this page shows the close of . Not investment advice.
Key figures
| Share price (delayed close) | $109.67 |
| Market cap | $6.5B |
| 52-week range | $49.57 - $146.67 |
| P/E | 109.2x |
| P/E, own 7-year median | 70.8x |
| P/S | 3.7x |
| Free cash flow yield | 4.3% |
| Dividend yield | - |
| Revenue (TTM) | $1.8B |
| Net income (TTM) | $60M |
| Free cash flow (TTM) | $280M |
| Gross margin | 74.4% |
| Operating margin | 7.2% |
| Return on equity | 5.1% |
| Revenue growth (1y) | +31.2% |
| Revenue CAGR (3y) | +41.4% |
| Debt / equity | 0.71x |
| Cash & short-term investments | $344M |
| Shares outstanding | 59m (cover page of the latest filing, 2026-07-30) |
The score: 18 of 36 checks passed
Six chapters, six pass/fail checks each. Five are computed from the filings; Trend is price behaviour, and says so.
Is ELF stock cheap or expensive right now?
Value · 1 of 6 checks passed. Expensive against its own history and its sector - you're paying up for what you get. chapter →
Is e.l.f. Beauty still growing?
Growth · 3 of 6 checks passed. Growing, but with caveats - revenue +31.2% over the last year. chapter →
Does e.l.f. Beauty make real money?
Quality · 3 of 6 checks passed. A solidly profitable business, though not exceptional against its sector. chapter →
Can e.l.f. Beauty survive a bad year?
Health · 5 of 6 checks passed. A fortress balance sheet - ELF can survive a very bad year. chapter →
What does e.l.f. Beauty hand back to shareholders?
Shareholder returns · 2 of 6 checks passed. What comes back to owners is thin or stretched - read the checks before counting on it. chapter →
Which way is ELF trending?
Trend analysis · 4 of 6 checks passed. Mixed signals from the market - some trends up, some rolling over. chapter →
Are insiders buying or selling ELF?
Open-market buys: $0.00 · sells: $16M, across the recent Form 4 filings. detail →
Other pharma and chemicals we cover: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · Procter & Gamble (PG) · Amgen (AMGN) · every company →
Method: figures computed deterministically from SEC EDGAR XBRL (companyfacts, frames, financial-statement-and-notes datasets, Form 4); prices delayed end-of-day. Scores count transparent pass/fail checks. Missing data is shown as missing, never estimated. Last changed . © TenQ - cite with a link to this page.